Industrial Policy & Trade Monitor· 2663 actions· ✨ 89 recent

On 1 May 2026 the trade pillar of the EU-Mercosur Partnership Agreement (the "Interim Trade Agreement", iTA) entered provisional application between the European Union and the four Mercosur states — Argentina, Brazil, Paraguay and Uruguay — following its publication in the EU Official Journal on 27 February 2026 alongside the broader EU-Mercosur Partnership Agreement (EMPA). The iTA covers goods (eliminating duties on more than 90% of bilateral trade over a transition period including immediate cuts on cars, pharmaceuticals, wine and olive oil), services, government procurement at federal and state level, intellectual property (344 EU geographical indications protected), SPS/TBT disciplines, and a sustainability chapter. Mercosur receives tariff-rate quotas on agri-food exports (beef, poultry, sugar, ethanol, honey). Provisional application proceeds pending full ratification of EMPA by the Council, European Parliament and all EU national parliaments and a pending CJEU opinion; only the trade pillar applies provisionally.

The European Investment Bank signed a EUR 400 million, seven-year loan agreement with Swedish hygiene and health group Essity on 29 January 2026 (EIB project ref. 20210374, "Essity Health and Hygiene Products RDI") to finance research, development and innovation expenditure at Essity's R&D centres in Sweden, Germany and France over 2025-2028. The financing targets product and process development across Personal Care, Professional Hygiene and medical wound care, with emphasis on replacing fossil-based plastics with bio-based materials, cutting greenhouse-gas emissions and expanding digital manufacturing solutions; roughly 30% of the RDI spend is earmarked for feminine-care and incontinence-product research. Global Trade Alert separately logs the transaction as a "red"-flagged state-linked lending intervention (state act 96020 / intervention 151945).

On 27 January 2026 the European Union and India announced the conclusion of negotiations on a comprehensive Free Trade Agreement at the EU-India summit hosted at Hyderabad House in New Delhi, attended by PM Narendra Modi, Commission President Ursula von der Leyen and Council President António Costa. The deal — described by both leaders as the "mother of all deals" — covers ~25% of world GDP and ~2 billion people. The EU eliminates duties on 91% of tariff lines (covering 99.3% of bilateral trade by value); India eliminates duties on 86% of lines (covering 96.6% by value). Headline cuts include Indian tariffs on EU wines (150% → 75% at entry into force, falling to 20%), olive oil (45% → 0% over five years) and processed agri-food (up to 50% eliminated); EU tariffs are reduced/eliminated on Indian textiles, leather/footwear, gems and jewelry, marine products, tea, coffee, spices and certain agricultural and steel products. The agreement still requires Council adoption, European Parliament consent and approval by India's Union Council of Ministers; entry into force is expected in early 2027. Companion instruments concluded at the same summit include an EU-India Security and Defence Partnership and a Mobility and Migration Agreement.

On 16 December 2025 the European Commission adopted in Strasbourg the Proposal for a Regulation establishing a framework of measures for strengthening the Union's biotechnology and biomanufacturing sectors particularly in the area of health — the "European Biotech Act" (COM(2025) 1022 final). The proposal is the third axis of the EU's pharma/biotech industrial-policy stack alongside the Critical Medicines Act (filed: 2025-03-11-eu-critical-medicines-act-proposal) and the US Section 232 pharmaceuticals track (filed: 2026-04-02-us-section-232-pharmaceutical-proclamation), and is explicitly designed to keep biotech innovation, investment, and biomanufacturing capacity in Europe in the face of US/China competitiveness pressure. Core instruments: (1) statutory recognition for "Health Biotechnology Strategic Projects" (HBSPs) and "High-Impact" HBSPs eligible for accelerated permitting via a single national contact point, plus administrative/technical/ financial support; (2) regulatory sandboxes for novel biotech and biomanufacturing modalities; (3) a 12-month Supplementary Protection Certificate extension for qualifying biotech and advanced-therapy medicines; (4) targeted simplification of existing EU life-sciences acquis (clinical-trial timelines, risk-proportionate requirements); (5) an EU Health Biotechnology Investment Pilot co-developed with the EIB Group, paired with a EUR 10bn 2026-27 EIB-Commission financing initiative; (6) biosecurity safeguards including a list of "biotechnology products of concern" and mandatory built-in screening for benchtop nucleic-acid synthesis devices. A second tranche covering industrial biotechnologies and biomanufacturing outside health is expected later in 2026.

In the early hours of 11 December 2025 the Council of the EU and the European Parliament reached provisional political agreement in trilogue on the "EU Pharma Package" — the revised pharmaceutical Regulation (COM 2023/0131) and Directive (COM 2023/0132) — the most significant overhaul of EU pharmaceutical legislation in over two decades. The package replaces Directive 2001/83/EC (Community Code on medicinal products for human use) and Regulation (EC) 726/2004 (the EMA Regulation), and consolidates the orphan-medicine (Regulation 141/2000) and pediatric-medicine regulations into a single framework. Headline provisions: (i) a new "8+1(+1)(+1)" IP-incentive architecture — 8 years of regulatory data protection plus 1 year of market protection, with up to two additional 12-month extensions for products addressing unmet medical need or new active substances meeting comparative-trial conditions, capped at 11 years total; (ii) an EU-wide list of critical medicines under enhanced governance via the Medicines Shortages Steering Group (MSSG) and an EMA "list of critical shortages in the EU"; (iii) mandatory shortage-prevention plans on marketing-authorisation holders for prescription medicines and Commission-designated products; (iv) modernisation of clinical-trial requirements, environmental-risk assessment, antimicrobial stewardship, and a transferable-exclusivity-voucher (TEV) regime to incentivise novel antibiotic R&D. The COREPER I committee endorsed the compromise text on 6 March 2026 and final adoption by Parliament and Council is expected during summer 2026, with the regulatory framework becoming applicable in 2028.

The European Commission approved German State aid of €47 million to Vetter Pharma, a family-owned contract development and manufacturing organisation (CDMO), to support a new aseptic fill-finish plant for injectable pharmaceuticals in Saarlouis, Saarland. The grant is part of a larger ~€480 million first construction phase of the site, which the Commission cleared under EU State aid rules citing job creation (up to 2,000 positions long-term), regional development in Saarland, and consistency with the EU Pharmaceutical Strategy for Europe's goal of securing affordable-medicines manufacturing capacity in the bloc.

The European Commission adopted Implementing Regulation (EU) 2025/1901 on 22 September 2025, imposing definitive anti-dumping duties on imports of glyoxylic acid (CAS 298-12-4, purity ≥95%, CN code ex 2918 30 00, TARIC 2918300013) originating in China for five years. Duty rates are differentiated by exporter: Hubei Hongyuan 29.2%, Xinjiang Guolin 130.0%, other cooperating producers 64.0%, and all non-cooperating Chinese imports 210.5%. The regulation definitively collects provisional duties previously imposed under Regulation (EU) 2025/591 (up to 280.3% provisional rates) from 24 March 2025.

The European Investment Bank signed a EUR 150 million loan agreement with Italian pharmaceutical group Alfasigma SpA on 8 July 2025 to finance the company's 2025-2027 research and development programme in rare diseases and specialty care (gastroenterology/hepatology, vascular medicine, rheumatology). The EIB framed the operation as part of its agenda to bolster competitiveness and innovation in the European healthcare sector. Global Trade Alert logged the announcement and implementation date as 27 June 2025 (state-act 92597); the EIB's own press release places the signing on 8 July 2025.

On 11 March 2025 the European Commission published its proposal for a Critical Medicines Act (CMA), pillar of the broader EU pharmaceutical-resilience agenda alongside the EU Critical Raw Materials Act (filed: 2024-05-23-eu-crma-entry-into-force) and the IRA-style industrial-policy stack. The proposal targets supply security of an EU "Union List" of critical medicines (antibiotics, anti-thrombotics, oncology, cardiovascular, insulin, painkillers) by introducing four mechanisms: (1) Strategic Project status with expedited funding access for critical-medicine manufacturing or active-substance production; (2) public-procurement preferences favouring resilient supply chains and — in defined cases — EU-based production; (3) collaborative cross-Member-State procurement to address fragmented small markets; (4) state-aid framework guidance + international-partnership diversification to reduce single-country (often China-routed) API dependency.

Directive (EU) 2022/2555 of the European Parliament and of the Council of 14 December 2022 on measures for a high common level of cybersecurity across the Union (NIS 2 Directive), published OJ L 333, 27 December 2022, entered into force 16 January 2023. NIS2 repeals and substantially expands the 2016 NIS1 Directive (2016/1148), extending the scope from ~7 sectors to 18 enumerated essential and important sectors, imposing binding cybersecurity risk- management and incident-reporting obligations on covered entities, introducing board-level management accountability, and mandating Member State transposition by 17 October 2024. NIS2 is the structural EU statutory anchor for national cybersecurity frameworks across the bloc, operating alongside DORA (Reg 2022/2554) for financial-sector digital resilience and CRA (Reg 2024/2847) for product cybersecurity.

Council Regulation (EU) 2022/2372, adopted 24 October 2022, establishes a binding framework empowering HERA (Health Emergency Preparedness and Response Authority) to activate emergency supply measures for crisis-relevant medical countermeasures — vaccines, therapeutics, PPE, medical devices, and in-vitro diagnostics — when a public health emergency at Union level is declared under Regulation (EU) 2022/2371. Emergency-mode powers include joint procurement on behalf of Member States, mandatory information requests to manufacturers on stockpiles and production capacity, accelerated R&D funding under the Emergency Research and Innovation Plan, and Union-level stockpile authority. This is the foundational binding instrument for the EU's post-COVID medical supply-chain resilience architecture; it is referenced by every subsequent EU pharma-resilience initiative including the Critical Medicines Act proposal (2025) and the 2025 MCM Strategy.